Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Developers seek to finetune toxicity of T-cell therapies.

Literature DB >> 25489817

Developers seek to finetune toxicity of T-cell therapies.

Chris Morrison.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2014 PMID： 25489817 DOI： 10.1038/nbt1214-1171

Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908

× No keyword cloud information.

4 in total

1. CAR-T cell therapy seeks strategies to harness cytokine storm.

Authors: Laura DeFrancesco
Journal: Nat Biotechnol Date: 2014-07 Impact factor: 54.908

2. Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors: Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal: N Engl J Med Date: 2014-10-16 Impact factor: 91.245

3. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

Authors: Sonia Guedan; Xi Chen; Aviv Madar; Carmine Carpenito; Shannon E McGettigan; Matthew J Frigault; Jihyun Lee; Avery D Posey; John Scholler; Nathalie Scholler; Richard Bonneau; Carl H June
Journal: Blood Date: 2014-07-01 Impact factor: 22.113

4. Inducible apoptosis as a safety switch for adoptive cell therapy.

Authors: Antonio Di Stasi; Siok-Keen Tey; Gianpietro Dotti; Yuriko Fujita; Alana Kennedy-Nasser; Caridad Martinez; Karin Straathof; Enli Liu; April G Durett; Bambi Grilley; Hao Liu; Conrad R Cruz; Barbara Savoldo; Adrian P Gee; John Schindler; Robert A Krance; Helen E Heslop; David M Spencer; Cliona M Rooney; Malcolm K Brenner
Journal: N Engl J Med Date: 2011-11-03 Impact factor: 91.245

4 in total

3 in total

Developers seek to finetune toxicity of T-cell therapies.

1. CAR-T cell therapy seeks strategies to harness cytokine storm.

2. Chimeric antigen receptor T cells for sustained remissions in leukemia.

3. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

4. Inducible apoptosis as a safety switch for adoptive cell therapy.

1. CAR-T field booms as next-generation platforms attract big players.

Review 2. Microfluidic models for adoptive cell-mediated cancer immunotherapies.

Review 3. Genetically modified T cells in cancer therapy: opportunities and challenges.